CINECA IRIS Institutional Research Information System

GALIMBERTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.612
EU - Europa 12.146
AS - Asia 5.021
AF - Africa 370
SA - Sud America 76
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 17
Totale 45.271
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.668
IT - Italia 4.824
CA - Canada 2.929
CN - Cina 2.386
SE - Svezia 2.230
BG - Bulgaria 1.143
SG - Singapore 1.128
PL - Polonia 987
DE - Germania 827
TR - Turchia 621
GB - Regno Unito 564
VN - Vietnam 493
UA - Ucraina 387
FI - Finlandia 370
RU - Federazione Russa 221
CI - Costa d'Avorio 210
CH - Svizzera 174
IN - India 152
HK - Hong Kong 145
FR - Francia 137
BE - Belgio 88
SN - Senegal 81
BR - Brasile 53
AT - Austria 49
NG - Nigeria 39
NL - Olanda 39
JP - Giappone 36
CZ - Repubblica Ceca 24
AU - Australia 22
BJ - Benin 18
EG - Egitto 16
EU - Europa 16
GR - Grecia 16
ES - Italia 14
KR - Corea 13
IE - Irlanda 11
RO - Romania 11
LT - Lituania 8
NZ - Nuova Zelanda 7
CL - Cile 6
ID - Indonesia 6
IR - Iran 6
MX - Messico 6
DK - Danimarca 5
EC - Ecuador 5
IL - Israele 5
BT - Bhutan 4
IQ - Iraq 4
MY - Malesia 4
HU - Ungheria 3
PE - Perù 3
PT - Portogallo 3
SC - Seychelles 3
TW - Taiwan 3
AR - Argentina 2
BD - Bangladesh 2
BO - Bolivia 2
CR - Costa Rica 2
EE - Estonia 2
HR - Croazia 2
KZ - Kazakistan 2
NI - Nicaragua 2
PA - Panama 2
PR - Porto Rico 2
RS - Serbia 2
SA - Arabia Saudita 2
TH - Thailandia 2
TN - Tunisia 2
UZ - Uzbekistan 2
A1 - Anonimo 1
AL - Albania 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CO - Colombia 1
ET - Etiopia 1
GY - Guiana 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MD - Moldavia 1
MT - Malta 1
PK - Pakistan 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VE - Venezuela 1
Totale 45.271
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.165
Fairfield 2.534
Ann Arbor 2.397
Montreal 2.302
Serra 2.005
Houston 1.992
Chandler 1.818
Santa Clara 1.632
Ashburn 1.302
Milan 1.209
Sofia 1.140
Seattle 1.099
Beijing 906
Wilmington 871
Cambridge 829
New York 725
Princeton 635
Boardman 627
Singapore 607
Ottawa 587
Jacksonville 565
Lawrence 458
Medford 440
Izmir 422
Nanjing 311
Des Moines 232
Abidjan 210
Florence 200
Dearborn 198
Istanbul 177
Dong Ket 169
San Diego 167
Bern 159
Nanchang 155
Rome 138
London 136
Hong Kong 135
Redwood City 120
Jüchen 98
Bremen 94
Hebei 90
Brussels 86
Shenyang 83
Dakar 81
Lancaster 81
Pisa 77
Kunming 73
Ogden 71
Changsha 70
Fuzhou 68
Frankfurt am Main 62
Hefei 57
Los Angeles 57
Shanghai 51
Boulder 49
Jiaxing 48
Westminster 46
Norwalk 45
Vienna 43
Hangzhou 40
Lagos 39
Alessandria 38
Chicago 37
Washington 36
Guangzhou 35
Pune 35
Tianjin 35
San Jose 31
Düsseldorf 30
Quanzhou 29
Orange 27
Dallas 26
Phoenix 26
Chengdu 24
Auburn Hills 21
Detroit 21
Wuhan 21
Hyderabad 20
Falls Church 19
Helsinki 19
Cotonou 18
Nürnberg 18
Toronto 16
Costa Mesa 15
Lanzhou 15
Livorno 14
Jinan 13
Duncan 12
Monza 12
San Francisco 12
Hamilton 11
Kilburn 11
New Delhi 11
Changchun 10
Palermo 10
Shenzhen 10
Sydney 10
Zhengzhou 10
Council Bluffs 9
Fremont 9
Totale 35.059
Salva come PNG Salva come JPEG
Nome #
EFFICACY AND TOXICITY PROFILES OF LOW-DOSE THALIDOMIDE AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS AFTER DOUBLE OR TRIPLE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. 3.366
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 212
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 195
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 194
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 178
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 177
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 175
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology 172
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 170
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 168
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 167
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 165
Characterization of Ph-negative abnormal clones emerging during imatinib therapy 164
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 164
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 163
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 160
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 160
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 160
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment 158
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 157
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 156
Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA 155
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 154
Correspondence between salivary proteomic pattern and clinical course in primary Sjogren syndrome and non-Hodgkin's lymphoma: a case report 154
Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma. 152
WT1 GENE EXPRESSION IS SIGNIFICANTLY INHIBITED BY VORINOSTAT AND BORTEZOMIB IN MYELOPROLIFERATIVE/MYELODISPLASTIC DISEASES 151
Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report., LEUKEMIA RESEARCH,pp 00,tot.pag 00,tot. autori 7,2007 150
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 150
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 149
Unexpected cardiotoxicity in haematological bortezomib treated patients 146
Expression of MDR1, MRP, TOPOISOMERASE-IIa, TOPOISOMERASE-IIb and GSTp in acute leukemias. 144
90y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group 143
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 143
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 142
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 141
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 141
Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA 141
PS-341 (Bortezomid) inhibits both proliferation of megakaryoblastic cells in vitro and MK colonies production in patients affected by idiopathic myelofibrosis 139
PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells 138
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 138
Panobinostat for the treatment of acute myelogenous leukemia 137
BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY. 136
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib 136
Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. 135
Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure 135
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 135
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 135
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. 135
Gelatin/PLLA sponge-like scaffolds allow proliferation and osteogenic differentiation of human mesenchymal stromal cells 135
Actin polymerization in neutrophils from donors of peripheral blood stem cells: divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor 134
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma 134
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 133
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 133
HISTONE DEACETYLASE INHIBITOR ITF2357 EXERT SIGNIFICANT ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS ON THE P39 CELL LINE: A GENE EXPRESSION STUDY 132
P112 gene expression patterns in MDS with del5q before and during lenalidomide treatment 132
Good manufacturing practice-grade fibrin gel is useful as a scaffold for human mesenchymal stromal cells and supports in vitro osteogenic differentiation 132
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 132
Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma 131
Predictive role of WT1 and RPS14 expression in patients affected by myelodysplastic syndromes receiving azacitidine 130
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 130
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview 130
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 129
R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL) 129
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 129
PLATELET-DERIVED GROWTH FACTOR BETA RECEPTOR (PDGFRB) GENE IS REARRANGED IN A SIGNIFICANT PERCENTAGE OF MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE 129
Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission 128
Suspension of Bone Marrow-Derived Undifferentiated Mesenchymal Stromal Cells for Repair of Superficial Digital Flexor Tendon in Race Horses. Tissue Eng. 2007 Oct 5 128
Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. 128
Unusual association of endometrial cancer and multiple myeloma 128
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 128
Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis 127
Other mechanisms to explain the role of reduced folate carrier in cancer 127
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 127
Early Diagnosis of Neutropenic Enterocolitis by Ultrasound Sonography. 126
Missense mutations in the PML-RAR alpha ligand binding domain in ATRA resistant Arsenic trioxide sensitive relapsed acute promyelocytic leukemia 126
PEG-Filgrastim activity on granulocyte functions 126
Low dose 2-CdA schedule activity in splenic marginal zone lymphomas 125
SAHA INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN A MEGAKARYOBLASTIC CELL LINE AND SYNERGISTICALLY INTERCATCS WITH THE PORTEASOME INHIBITOR BORTEZOMIB. 125
MDS: An Integrated Workup for a Correct Diagnosis 125
Clinical Applications of Nuclear Medicine: Multiple Myeloma 125
Hairy Cell Leukemia. 124
INDUCTION OF COMPLETE MOLECULAR RESPONSE WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN®) IN B CELL NON HODGKIN’S LYMPHOMA PATIENTS AFTER THE ACHIEVEMENT OF A COMPLETE CLINICAL RESPONSE WITH CHEMOTHERAPY REGIMEN 124
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in ch 124
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients 124
Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study 124
A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13) 124
Dose-dependent induction of apoptosis by R-apomorphine in CHO-K 1 cell line in culture 124
MDR1 polymorphism influences the outcome of multiple myeloma patients 124
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 124
Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy. 123
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study 123
Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis. 123
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib 123
Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study 122
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND THEIR RELATIONSHIP WITH CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA 122
MDR1 polymorphism influences the outcome of multiple myeloma patients 122
How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases 122
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 122
Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation. 121
A myeloablative allograft after rejection of two consecutive nonmyeloablative transplants from two different HLA identical siblings 121
Totale 17.229
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.833
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.833
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.052 0 0 0 0 0 750 863 558 682 481 578 140
2020/20213.535 261 181 204 153 287 144 393 287 343 214 380 688
2021/20225.477 163 363 141 344 923 661 159 235 447 154 364 1.523
2022/20235.801 916 813 385 550 576 701 54 463 876 45 356 66
2023/20248.144 607 561 562 370 720 803 232 106 67 3.358 187 571
2024/20253.577 66 566 123 789 1.154 879 0 0 0 0 0 0
Totale 46.146